Jane Anne Nohl Division of Hematology and Center for the study of Blood disease, Division of Hematology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, USA
Auto-generated profile, based on publicly available information
George Yaghmour
Jane Anne Nohl Division of Hematology and Center for the study of Blood disease, Division of Hematology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, USA
Activating mutations in FLT3 in acute myeloid leukemia (AML) portend a poor prognosis, and targeting FLT3 with a tyrosine kinase inhibitor has been an area of intense research recently. Most FLT3 mutated AML patients undergo hematopoietic stem cell transplantation (HSCT) as standard of care but a significant proportion of patients relapse. Although the use of FLT3 inhibitors in the pre-HSCT perspective is more clearly defined, its use in the post-HSCT scenario, when most relapses occur, remains unclear. In this review, we comprehensively present the data on the recent and ongoing studies evaluating the role of various FLT3 inhibitors in AML with a particular focus in the post-HSCT setting.
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.